As already mentioned above, although the recent introduction of an SGLT2-i in the treatment of T2DM patients has focused attention on the correlation between euDKA and the use of these drugs, some of the above-listed conditions could cause this form of DKA regardless of the SGLT2-i administration. Here, SLC5A2 is linked to type 2 diabetes mellitus.